Kafadar, A. Et Al. 2015. Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors. ANTICANCER RESEARCH , vol.35, no.7 , 3933-3942.

Kafadar, A., Kucukhuseyin, Ö., Turan, S., Yenilmez, E. N., Tunoglu, S., Zeybek, U., ... Kaynar, M. Y.(2015). Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors. ANTICANCER RESEARCH , vol.35, no.7, 3933-3942.

Kafadar, Ali Et Al. "Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors," ANTICANCER RESEARCH , vol.35, no.7, 3933-3942, 2015

Kafadar, Ali M. Et Al. "Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors." ANTICANCER RESEARCH , vol.35, no.7, pp.3933-3942, 2015

Kafadar, A. Et Al. (2015) . "Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors." ANTICANCER RESEARCH , vol.35, no.7, pp.3933-3942.

@article{article, author={Ali Metin KAFADAR Et Al. }, title={Distribution and Effects of CDKN2 p16 540 C > G and 580 C > T, and MDM2 SNP309 T > G Polymorphisms in Patients with Primary Brain Tumors}, journal={ANTICANCER RESEARCH}, year=2015, pages={3933-3942} }